GlobeNewsWire
14 Jul 2026, 11:45 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Hemab Therapeutics plans to initiate Phase 3 trials for sutacimig in the second half of 2026 following FDA alignment on dose and regimen. — Advancement to Phase 3 is a major regulatory milestone that significantly derisks the lead asset and brings the company closer to potential commercialization.
+0.60Phase 2 long-term extension data for sutacimig demonstrated sustained bleed reduction and a manageable safety profile in patients with Glanzmann thrombasthenia. — Positive durability and safety data in a patient population with no approved prophylaxis increase the probability of Phase 3 success.
+0.50Preclinical data for sutacimig in Factor VII deficiency showed restoration of thrombin generation, supporting its potential use as a pan-hemostatic agent. — Expanding the potential indication to Factor VII deficiency increases the total addressable market (TAM) for the drug.
+0.30Which stocks this story touches
Continue reading
6 related stories
Search tags
The company reported positive Phase 2 data for sutacimig, including sustained bleed reduction, and announced plans to initiate Phase 3 trials.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
1d ago
